Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (13253)	9/30/2004 5:14:57 PM
From: Biomaven	Respond to of 52153

Do we know that the increase in risk is CAUSED by taking Viox and not by the absence of taking aspirin? Now we do because we have a placebo controlled trial. Vioxx does substantially worse than placebo. A few months back we only had comparisons with Naprosyn, which was hard, because nobody really knows what effect Naprosyn has on cardiac risk. (An expert told me that he thinks that if you take it twice a day it acts like aspirin and cuts risk, but if you take it less often it doesn't). Peter